Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine’s (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations.

Diabetes disproportionately impacts underserved communities, driven by socioeconomic disparities, inadequate healthcare access, and systemic injustices. Despite advancements in pharmacotherapy with GLP-1s and the increase in availability of innovative devices like continuous glucose monitors, diabetes prevalence continues to rise, and only about 50% of adults with diabetes achieve glycemic control. This underscores the urgent need for evidence-based interventions to ensure equitable access to high-quality care for all.

Lifestyle medicine is a medical specialty that uses therapeutic lifestyle interventions to treat chronic conditions, including cardiovascular diseases, type 2 diabetes, and obesity, and, when used intensively, can often reverse such conditions.

The Lifestyle Medicine National Training Initiative (NTI) is an extension of ACLM’s $24.1 million commitment to the 2022 White House Conference on Hunger, Health, and Nutrition. It commits more than $2 million in matching funds to train primary care providers in lifestyle medicine within each FQHC and Community Health Center (CHC) across the United States. AspyreRx complements this important initiative by helping to ensure that a scalable, lifestyle medicine digital therapeutic is broadly accessible, regardless of socioeconomic status or geographic location.

“This innovative partnership demonstrates our joint commitment to addressing disparities in healthcare access and promoting the adoption of lifestyle medicine clinician training coupled with evidence-based treatments,” said Mark Berman, MD, FACLM, chief medical officer at Better Therapeutics. “With our robust clinical data including strong representation from these underserved communities, we’re uniquely positioned to showcase the transformative potential of software-based interventions, offering more efficient and effective treatments compared to current behavioral programs. By scaling up, we can break down barriers to care and drive significant health outcomes in often neglected communities.”